Cite
177Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer
MLA
Rasaneh, Samira, et al. “177Lu Labeling of Herceptin and Preclinical Validation as a New Radiopharmaceutical for Radioimmunotherapy of Breast Cancer.” Nuclear Medicine & Biology, vol. 37, no. 8, Nov. 2010, pp. 949–55. EBSCOhost, https://doi.org/10.1016/j.nucmedbio.2010.07.001.
APA
Rasaneh, S., Rajabi, H., Babaei, M. H., & Daha, F. J. (2010). 177Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer. Nuclear Medicine & Biology, 37(8), 949–955. https://doi.org/10.1016/j.nucmedbio.2010.07.001
Chicago
Rasaneh, Samira, Hossein Rajabi, Mohammad Hossein Babaei, and Fariba Johari Daha. 2010. “177Lu Labeling of Herceptin and Preclinical Validation as a New Radiopharmaceutical for Radioimmunotherapy of Breast Cancer.” Nuclear Medicine & Biology 37 (8): 949–55. doi:10.1016/j.nucmedbio.2010.07.001.